Related references
Note: Only part of the references are listed.Treatment with the radiolabeled somatostatin analog [177Lu-DOTA0, Tyr3] octreotate:: Toxicity, efficacy, and survival
Dik J. Kwekkeboom et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Initial direct comparison of 99mTc-TOC and 99mTc-TATE in identifying sites of disease in patients with proven GEP NETs
Jaroslaw B. Cwikla et al.
JOURNAL OF NUCLEAR MEDICINE (2008)
Consensus guidelines for the management of patients with digestive neuroendocrine tumors - Well-differentiated jejunal-ileal tumor/carcinoma
Barbro Eriksson et al.
NEUROENDOCRINOLOGY (2008)
Comparison of [177Lu-DOTA0, Tyr3] octreotate and [177Lu- DOTA0, Tyr3] octreotide:: which peptide is preferable for PRRT?
J. P. Esser et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2006)
Measuring response in a post-RECIST world: from black and white to shades of grey
LC Michaelis et al.
NATURE REVIEWS CANCER (2006)
Large-volume liver metastases from neuroendocrine tumors:: Hepatic intraarterial 90Y-DOTA-lanreotide as effective palliative therapy
MKG McStay et al.
RADIOLOGY (2005)
Guidelines for the diagnosis and treatment of neuroendocrine gastrointestinal tumours - A consensus statement on behalf of the European Neuroendocrine Tumour Society (ENETS)
U Plockinger et al.
NEUROENDOCRINOLOGY (2004)
Treatment of patients with gastro-entero-pancreatic (GEP) tumours with the novel radiolabelled somatostatin analogue [177Lu-DOTA0,Tyr3]octreotate
DJ Kwekkeboom et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2003)
Somatostatin receptor-targeted radionuclide therapy of tumors: Preclinical and clinical findings
M de Jong et al.
SEMINARS IN NUCLEAR MEDICINE (2002)
Receptor-mediated radiotherapy with 90Y-DOTA-DPhe1-Tyr3-octreotide:: The experience of the European Institute of Oncology Group
M Chinol et al.
SEMINARS IN NUCLEAR MEDICINE (2002)
End-stage renal disease after treatment with 90Y-DOTATOC
M Cybulla et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE (2001)
Somatostatin receptor-mediated imaging and therapy: basic science, current knowledge, limitations and future perspectives
WAP Breeman et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE (2001)
[177Lu-DOTA0,Tyr3]octreotate:: comparison with [111In-DTPA0]octreotide in patients
DJ Kwekkeboom et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE (2001)
The clinical value of [90Y-DOTA]-D-Phe1-Tyr3-octreotide (90Y-DOTATOC) in the treatment of neuroendocrine tumours:: A clinical phase II study
C Waldherr et al.
ANNALS OF ONCOLOGY (2001)
Receptor-mediated radiotherapy with 90Y-DOTA-D-Phe1-Tyr3-octreotide
G Paganelli et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE (2001)
Affinity profiles for human somatostatin receptor subtypes SST1-SST5 of somatostatin radiotracers selected for scintigraphic and radiotherapeutic use
JC Reubi et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE (2000)
Share Paper
